Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits

Medicine & Life Sciences

• Protease Inhibitors 87%
• Saquinavir 82%
• Indinavir 80%
• Ritonavir 71%
• HIV 58%
• Biological Availability 51%
• HIV Protease Inhibitors 41%
• Viruses 37%
• Salvage Therapy 33%
• Cytochrome P-450 CYP3A 32%
• Drug Combinations 29%
• Drug Interactions 27%
• Meals 25%
• Capsules 25%
• HIV Infections 25%
• Peptide Hydrolases 23%
• Pharmaceutical Preparations 23%
• Eating 21%
• Pharmacokinetics 21%
• Food 19%
• Clinical Trials 18%
• Morbidity 16%
• Liver 14%
• Mortality 14%
• Therapeutics 13%

Chemical Compounds

• Protease Inhibitor 100%
• Saquinavir 69%
• Indinavir 69%
• Clearance 68%
• Ritonavir 65%
• Drug 44%
• Bioavailability 41%
• HIV Protease Inhibitor 31%
• Antiretroviral 30%
• Cytochrome P450 22%
• Metabolic 17%
• Pharmacological Metabolism 16%
• Dose 16%
• Pharmacokinetics 15%
• Food 15%
• Block Like Crystal 14%
• Reduction 9%